Clinical trial
A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to…
NCT04488133 · Biogen, Industry · Completed
Key facts
| NCT number | NCT04488133 |
|---|---|
| Title | A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND) |
| Official title | A Phase 4 Study of Nusinersen (BIIB058) Among Patients With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec |
| Acronym | RESPOND |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Muscular Atrophy, Spinal |
| Intervention type | Drug |
| Interventions | Nusinersen |
| Enrollment | 46 |
| Start date | Jan 4, 2021 |
| Primary completion | Oct 9, 2025 |
| Completion | Oct 9, 2025 |
| First posted | Jul 27, 2020 |
| Last update posted | Oct 14, 2025 |
| Countries | Germany, Israel, Italy, Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: